Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial)
Phillip H. Kuo, Michael J. Morris, Jacob Hesterman, A. Tuba Kendi, Kambiz Rahbar, Xiao X. Wei, Bruno Fang, Nabil Adra, Rohan Garje, Jeff M. Michalski, Kim Chi, Johann S. de Bono, Karim Fizazi, Bernd J. Krause, Oliver Sartor, Scott T. Tagawa, Samson Ghebremariam, Marcia A. Brackman, Connie C Wong, Ana M. Catafau, Taylor L. Benson, Andrew J. Armstrong, Ken Herrmann
Abstract
Visual 68 Ga-PSMA-11 PET/CT eligibility criteria helped identify participants with metastatic castration-resistant prostate cancer who benefitted from 177 Lu-PSMA-617 therapy in the VISION trial, with higher 68 Ga-PSMA-11 uptake associated with improved outcomes.
Topics & Concepts
MedicineProstate cancerLutetiumNuclear medicineClinical trialOncologyProstateInternal medicineRadiologyCancerYttriumOxideOrganic chemistryChemistryProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsCancer, Lipids, and Metabolism